OncoStem provides prognostic services to patients with hormone-positive HER2-negative cancers conjointly with clinicians, allowing prediction of low and high-risk patients and providing a potential personalised treatment plan per the patient's requirements. This evidence concerns the gene ERBB2 and cancer.